InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Key Stats

• Today's Range: $2.36 to $2.50
• 50-Day Range: $2.22 to $2.79
• 52-Week Range: $1.99 to $3.80
• Volume: 56,922 shs
• Average Volume: 103,653 shs
• Market Capitalization: $73.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 72% of companies evaluated by MarketBeat, and ranked 269th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

InspireMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.23% of the outstanding shares of InspireMD have been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently increased by 17.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.23% of the outstanding shares of InspireMD have been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently increased by 17.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.91

News Sentiment

InspireMD has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for InspireMD this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for NSPR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

2 people have added InspireMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $249,996.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

34.06% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NSPR Stock Analysis - Frequently Asked Questions

How have NSPR shares performed this year?

InspireMD's stock was trading at $2.63 on January 1st, 2025. Since then, NSPR stock has decreased by 9.1% and is now trading at $2.39.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business earned $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%.

Who are InspireMD's major shareholders?

InspireMD's top institutional shareholders include Huntleigh Advisors Inc. (0.41%) and Vestia Personal Wealth Advisors (0.06%). Insiders that own company stock include Marvin Slosman, Gary S Roubin, Paul Stuka and Thomas J Kester.
View institutional ownership trends.

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NSPR
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InspireMD: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +87.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.92 million
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $7.03 million
• Price / Sales: 10.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 30,635,000
• Free Float: 18,332,000
• Market Cap: $73.71 million
• Optionable: Optionable
• Beta: 0.60